Table 5 Pathological Characteristics
|  |  | Conventional group (n = 101) | Combined group (n = 102) | P |
|---|---|---|---|---|
Pathological Type | Â | Â | 0.314 | |
| Â | Adenocarcinoma | 94 (93.1%) | 92 (90.2%) | Â |
| Â | Mucinous | 7 (6.9%) | 10 (9.8%) | Â |
Degree of differentiation | Â | Â | 0.661 | |
| Â | Poorly/Mucinous | 49 (48.5%) | 54 (52.9%) | Â |
| Â | Moderate | 51 (50.5%) | 46 (45.1%) | Â |
| Â | Well | 1 (1%) | 2 (2%) | Â |
T Stage | Â | Â | Â | 0.03 |
| Â | ypT0 | 5 (5%) | 17 (16.7%) | Â |
| Â | ypT1 | 7 (6.9%) | 9 (8.8%) | Â |
| Â | ypT2 | 23 (12.9%) | 17 (16.7%) | Â |
| Â | ypT3 | 54 (53.5%) | 42 (41.2%) | Â |
| Â | ypT4 | 12 (11.9%) | 18 (17.6%) | Â |
N Stage | Â | Â | Â | 0.055 |
| Â | ypN0 | 38 (37.6%) | 57 (55.9%) | Â |
| Â | ypN1 | 17 (16.8%) | 15 (14.7%) | Â |
| Â | ypN2 | 26 (25.7%) | 15 (14.7%) | Â |
| Â | ypN3 | 20 (19.8%) | 15 (14.7%) | Â |
M Stage | Â | Â | Â | 0.748 |
| Â | ypM0 | 97 (96%) | 96 (94.1%) | Â |
| Â | ypM1 | 4 (4%) | 6 (5.9%) | Â |
TRG | Â | Â | Â | 0.028 |
| Â | Grade 0 | 5 (5%) | 17 (16.7%) | Â |
| Â | Grade 1 | 18 (17.8%) | 23 (22.5%) | Â |
| Â | Grade 2 | 56 (55.4%) | 46 (45.1%) | Â |
| Â | Grade 3 | 22 (21.8%) | 16 (15.7%) | Â |
T Downstage | 79 (78.2%) | 75 (73.5%) | 0.512 | |
 N Downstage | 47 (46.5%) | 54 (52.9%) | 0.401 | |
Pathological Complete Response | 5 (5%) | 17 (16.7%) | 0.012 | |
Angiolymphatic invasion | 12 (11.9%) | 18 (17.6%) | 0.323 | |
Tumor deposit | 6 (5.9%) | 11 (10.8%) | 0.311 | |
HER2 positive | 13 (12.9%) | 9 (8.8%) | 0.376 | |